Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates

Day One Biopharmaceuticals, Inc. (DAWN) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.69 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -19.98%. A quarter ago, it was expected that this company would post a loss of $0.28 per share when it actually produced a loss of $0.19, delivering a surprise of +32.14%.Over the last four quarters, the ...